Results: 8

Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab

J. bras. pneumol; 47 (5), 2021
ABSTRACT Objective: To determine the prevalence of recurrent wheezing (RW) in preterm infants who received prophylaxis against severe infection with respiratory syncytial virus (RSV) and to identify genetic susceptibility (atopy or asthma) and risk factors for RW. Methods: This was a cross-sectional st...

Temporal trend of hospitalizations for acute bronchiolitis in infants under one year of age in brazil between 2008 and 2015

ABSTRACT Objective: To evaluate the trend of hospitalization for acute bronchiolitis in infants under one year of age, in the past eight years and after the implementation of the palivizumab immunization program in Brazil. Methods: The study is a retrospective analysis of data on infants younger than...

One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America

J. pediatr. (Rio J.); 93 (5), 2017
Abstract Objective: This study aims to describe real world palivizumab use and effectiveness in high-risk Latin American infants and young children. Method: Prospective, multicenter observational study with infants at risk for severe RSV infection who received palivizumab according to routine clinical ...

Uso de palivizumab en el control de un brote de VRS en una unidad de cuidado intensivo neonatal

Rev. pediatr. electrón; 14 (1), 2017
El virus respiratorio sincicial (VRS) es una causa importante de morbilidad en pediatría, especialmente en los menores de 2 años. Los grupo de mayor riesgo de presentar una infección grave son los recién nacidos prematuros (RNPrT) menores de 35 semanas de edad gestacional, los pacientes portadores de...

Informe de evaluación científica basada en la evidencia disponible: virus respiratorio sincicial
Scientific evaluation report based on available evidence: respiratory syncytial virus

INTRODUCCIÓN: La infección por Virus Respiratorio Sincicial (VRS) es una de las causas principales de infección aguda de las vías respiratorias inferiores en lactantes y niños en todo el mundo, provocando una carga importante de morbilidad y mortalidad. Palivizumab es un anticuerpo monoclonal indi...

Impact of the use of immunoglobulin palivizumab in the State of São Paulo: a cohort study

ABSTRACT Introduction: the use of palivizumab as prophylaxis of the respiratory syncytial virus is not a consensus. In Brazil, it is a public health program, but other countries do not consider it cost-effective. Objective: to identify the rate of hospitalization in Intensive Care Unit for respiratory ...

Atualizações no tratamento de bronquiolite viral aguda
Updates on acute bronchiolitis treatment

Rev. méd. Minas Gerais; 26 (supl. 2), 2016
Bronquiolite viral aguda consiste em uma afecção viral que acomete lactentes com idade inferior a dois anos, sendo o pico de incidência abaixo de seis meses de vida. O quadro clínico consiste em sintomas de infecção de vias aéreas superiores, que evolui após dois a quatro dias com cansaço, dispn...

Prevenção de Infecções pelo Vírus Sincicial Respiratório (VSR): uso do palivizumabe
Respiratory Syncytial Vírus (RSV) infection prevention: palivizumab use

Rev. méd. Minas Gerais; 26 (supl. 2), 2016
Introdução: o vírus sincicial respiratório (VSR) pode causar quadros graves de bronquiolites e pneumonias, principalmente em grupos de risco como prematuros, cardiopatas e portadores de pneumopatias. O palivizumabe (PVZ) trouxe grande avanço na prevenção dessa doença e, devido ao alto custo, a Se...